Skip to content

Study · Non-randomized trial · n = 14 · 1977

3 results

Serum somatomedin activity depressed after glucagon administration in man.

Binoux M, Schimpff RM, Donnadieu M

The Journal of clinical endocrinology and metabolism1 May 1977Cited by 7 (Europe PMC)

PMID858774 (opens in a new tab)DOI10.1210/jcem-44-5-1006 (opens in a new tab)PepBankPUB-00858774
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In subjects given glucagon, serum somatomedin activity decreased significantly at 30 and 60 minutes, while controls showed no significant change.

    In plain wordsGlucagon reduced serum somatomedin activity at 30 and 60 minutes, while controls showed no significant change.

    Peptide
    Glucagon
    Outcome
    DecreaseSerum somatomedin activity
    Study

    n = 14

    Comparator
    10 controls (control procedure not stated)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Measurements

    P value
    < 0.01 p
    SM activity decrease after glucagon at 30 and 60 min (upper bound of reported p range)
    P value
    < 0.001 p
    SM activity decrease after glucagon at 30 and 60 min (lower bound of reported p range)

    Source sentences

    Summary
    A significant decrease in SM activity was observed 30 and 60 min after glucagon (p less than 0.01 to less than 0.001) whereas no significant change was noted in the controls.
    1 context sentence
    Summary · context
    The variations in serum somatomedin (SM) activity were compared in 14 subjects after glucagon injection (1 mg im), and in 10 controls.
  2. 02HumanNon-randomized trialMechanism

    After glucagon, somatomedin activity changes did not correlate with changes in growth hormone, cortisol or fatty acids.

    In plain wordsAfter glucagon, somatomedin activity changes did not correlate with growth hormone, cortisol or fatty acid changes.

    Peptide
    Glucagon
    Outcome
    No significant changeSomatomedin activity correlations with growth hormone, cortisol and fatty acids
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    No correlation was found between the variations of growth hormone (GH), cortisol, or fatty acids and those of SM activity.
    1 context sentence
    Summary · context
    The variations in serum somatomedin (SM) activity were compared in 14 subjects after glucagon injection (1 mg im), and in 10 controls.
  3. 03HumanNon-randomized trialMechanism

    After glucagon administration, maximal changes in glycemia, insulin and somatomedin activity occurred during the same interval.

    In plain wordsAfter glucagon, the largest changes in blood glucose, insulin and somatomedin activity occurred during the same interval.

    Peptide
    Glucagon
    Outcome
    Not applicableTiming of maximum glycemia, insulin and somatomedin changes
    Study

    n = 14

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The maximum variations in glycemia, insulin and SM activity occured during the same time interval.
    1 context sentence
    Summary · context
    The variations in serum somatomedin (SM) activity were compared in 14 subjects after glucagon injection (1 mg im), and in 10 controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.